Intervention

Inclisiran

Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

RCT evidence— LDL-lowering proven; outcomes pending

What it is

Inclisiran is a small interfering RNA (siRNA) conjugated to a triantennary N-acetylgalactosamine (GalNAc) ligand that targets the asialoglycoprotein receptor on hepatocytes. Once delivered, the siRNA silences PCSK9 mRNA, reducing PCSK9 protein production, which in turn raises LDL receptor density and lowers plasma LDL.

The advantage

A single subcutaneous dose lasts ~6 months. Adherence is the single biggest barrier to LDL targets in real-world practice; an every-6-month office visit dramatically improves real-world LDL outcomes vs. daily pills.

What’s known

ORION-9, -10, -11 Phase-3 trials: ~50% LDL reduction sustained.
Safety: clean in trials to date.
Outcomes: ORION-4 large cardiovascular outcomes trial reading out later this decade. Until then, ezetimibe and PCSK9 mAbs have stronger outcomes data and are typically tried first.

Practical

Administered by clinicians in office (not self-injected). Schedule: day 0, month 3, then every 6 months. Stable LDL between doses with no "trough" effect.

References

Ray, K. K. et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol (ORION-10 and ORION-11). N. Engl. J. Med. 382, 1507–1519 (2020).